Results for the First Quarter 2023

25. Apr 2023

NOK 82.1. The Vascular business segment continues the positive development and grows at 21.5% in NOK, currency neutral 8.8% growth. The Imaging products grow at 9.4% in NOK, currency neutral decline of 3.7%. Currency neutral…

Annual Report 2022

31. Mar 2023

Further supported by several high-quality symposia at the largest heart surgery conferences, we achieved 44 % growth in the imaging product portfolio in 2022. And while steadily penetrating the Cardiac bypass market, we also build…

Results for the Fourth Quarter and Preliminary Results for 2022

1. Mar 2023

All major geographical regions drive sales growth. Currency-neutral sales increased by 21.6 % for the quarter and 11.9 % for the year. Currency-neutral sales of own products increase 24.6 % for the quarter and 14.0…

Capital Markets Day

27. Feb 2023

See the recording from Medistim's Capital Markets Day on March 21st where two international thought leaders, Professors John. D. Puskas and Pirkka Vikatmaa shared their insights on the future trends in Cardiac and Vascular Surgery…

Presentation of Medistim’s Q4 and preliminary year-end results 2022

20. Feb 2023

The financials will be presented via a live webinar on Wednesday, March 1st from 08:00-09:00 (CET). Representatives for the company will be Kari Eian Krogstad (CEO), and Thomas Jakobsen (CFO). The recording will be made available…

Annual Report 2021

30. Mar 2022

This rebound has continued throughout 2021, and Medistim has experienced strong growth in revenues due to the increase in number of CABG procedures performed. The sales growth was 17.6 % in NOK and operating profit…

Results for the Third Quarter 2021

22. Oct 2021

Sales revenues for the quarter ended at MNOK 102.1 (MNOK 83.4), an increase of 22.5%. Sales as of September ended at MNOK 309.2 (MNOK 268.9) a 15.0% increase. Sales in the USA increased by 11.9…

Results for the Second Quarter and First Half 2021

13. Aug 2021

Total revenues for the quarter ended at MNOK 109.8 (MNOK 82.5) and includes MNOK 5.3 granted by the U.S. Paycheck Protection Program related to COVID-19. Total revenues for the first half ended at MNOK 212.4…

Results for the First Quarter 2021

28. Apr 2021

Sales for the quarter ended at MNOK 102.6 (MNOK 103.1), on par with the sales record set in Q1 last year. Currency neutral, sales increased by 1.5%. Second best quarter ever for operating result (EBIT)…

Annual Report 2020

29. Mar 2021

Following a good start to the year, Medistim experienced a significant impact on operations in the first months of the pandemic. However, due to a solid revenue base and good pipeline activity throughout the second…

Name of cookie	Time of storage	Provider	Description
_ga	2 years	medistim.com	This cookie registers your unique ID upon your visit, to generate statistical data on how you use our website.
_gat	1 day	medistim.com	This cookie is used by Google Analytics to throttle the request rate.
_gid	1 day	medistim.com	This cookie registers a unique ID that is used to generate statistical data on how you use our website.
p.gif	Session	typekit.net	This cookie keeps track of special fonts used on the site for internal analysis. This cookie does not register any visitor data.

Name of cookie	Time of storage	Provider	Description
ads/ga.audiences	Session	google.com	This cookie is used by Google Adwords to re-engage visitors that are likely to convert to customers based on the visitor's online behaviour across websites
r/collect	Session	doubleclick.net	This cookie is used to send data to Google Analytics about the visitor's device and behavior. The cookie tracks visitors across devices and marketing channels.